An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder

In this unblinded randomised waitlist-controlled preprint, 37 people with OCD were assigned to immediate or delayed psilocybin and 30 completed the one-month analysis; a 20 mg session was followed by 30 mg if tolerated. OCD symptoms improved more than on the waitlist and remained lower after both groups received treatment, with no serious adverse events reported, although seven withdrew, including two after anxiety or panic.